Literature DB >> 24966267

Vincristine-induced polyneuropathy in a child with stage I Wilms' tumour presenting with unilateral abducens nerve palsy.

Panadeekarn Panjawatanan1, Pimlak Charoenkwan2, Kamornwan Katanyuwong2, Worawut Choeyprasert2.   

Abstract

A 4-year-old boy presented with right esotropia while receiving vincristine and dactinomycin for stage I Wilms' tumour according to the National Wilms Tumour Study-5 protocol. On examination, he had isolated limitation of his right lateral gaze. CT of the brain and cerebrospinal fluid examination were normal. A nerve conduction velocity study which was performed on the peripheral nerves revealed predominant motor polyneuropathy compatible with axonal loss involving the upper limbs. The patient had received a cumulative vincristine dose of 17 mg/m(2) before developing esotropia. Vincristine-induced abducens nerve mononeuropathy and subclinical motor polyneuropathy was suspected. Unilateral esotropia markedly improved after the discontinuation of vincristine and a short course of oral pyridoxine treatment. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24966267      PMCID: PMC4078428          DOI: 10.1136/bcr-2014-204524

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: a pilot study.

Authors:  Galila M Mokhtar; Sanaa Y Shaaban; Nancy Samir Elbarbary; Waleed A Fayed
Journal:  J Pediatr Hematol Oncol       Date:  2010-11       Impact factor: 1.289

2.  Toxic neuropathy in patients with pre-existing neuropathy.

Authors:  V Chaudhry; M Chaudhry; T O Crawford; E Simmons-O'Brien; J W Griffin
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

3.  Mechanism of inhibition of cell proliferation by Vinca alkaloids.

Authors:  M A Jordan; D Thrower; L Wilson
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

4.  Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation.

Authors:  Tomonori Nakamura; Akihiro Hashiguchi; Shinsuke Suzuki; Kimiharu Uozumi; Shoko Tokunaga; Hiroshi Takashima
Journal:  Neurogenetics       Date:  2012-01-25       Impact factor: 2.660

Review 5.  Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.

Authors:  J D Chan
Journal:  Pharmacotherapy       Date:  1998 Nov-Dec       Impact factor: 4.705

6.  Vincristine-induced peripheral neuropathy in a neonate with congenital acute lymphoblastic leukemia.

Authors:  Steven K Baker; David M Lipson
Journal:  J Pediatr Hematol Oncol       Date:  2010-04       Impact factor: 1.289

7.  Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.

Authors:  Jeffrey S Dome; Cecilia A Cotton; Elizabeth J Perlman; Norman E Breslow; John A Kalapurakal; Michael L Ritchey; Paul E Grundy; Marcio Malogolowkin; J Bruce Beckwith; Robert C Shamberger; Gerald M Haase; Max J Coppes; Peter Coccia; Morris Kletzel; Robert M Weetman; Milton Donaldson; Roger M Macklis; Daniel M Green
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

8.  Selective metabolism of vincristine in vitro by CYP3A5.

Authors:  Jennifer B Dennison; Palaniappan Kulanthaivel; Robert J Barbuch; Jamie L Renbarger; William J Ehlhardt; Stephen D Hall
Journal:  Drug Metab Dispos       Date:  2006-05-05       Impact factor: 3.922

9.  Bilateral vocal cord paralysis following treatment with vincristine.

Authors:  Rahul Naithani; Tuphan Kanti Dolai; Rajat Kumar
Journal:  Indian Pediatr       Date:  2009-01       Impact factor: 1.411

10.  Jaw and other orofacial pain in patients receiving vincristine for the treatment of cancer.

Authors:  G M McCarthy; J R Skillings
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1992-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.